Historically, treatment for advanced RCC relied on cytokine-based therapies, including interferon-alpha (IFN-α) and interleukin-2 (IL-2), which produced limited efficacy and significant toxicity [5]. This evidence concerns the gene IL2 and renal cell carcinoma.